HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[3H]A-585539 [(1S,4S)-2,2-dimethyl-5-(6-phenylpyridazin-3-yl)-5-aza-2-azoniabicyclo[2.2.1]heptane], a novel high-affinity alpha7 neuronal nicotinic receptor agonist: radioligand binding characterization to rat and human brain.

Abstract
Receptor binding was characterized for [(3)H](1S,4S)-2,2-dimethyl-5-(6-phenylpyridazin-3-yl)-5-aza-2-azoniabicyclo[2.2.1]heptane ([(3)H]A-585539), a selective high-affinity alpha7 nicotinic acetylcholine receptor (nAChR) agonist with rapid kinetics, low nonspecific binding, and high specific activity. At 4 degrees C, the association was monophasic and rapid (t((1/2)) = 8.0 min); dissociation was slower (t((1/2)) = 64.2 min). The K(d) in rat brain at 4 degrees C was 0.063 nM, whereas at 22 and 37 degrees C, the K(d) values were 0.188 and 0.95 nM, respectively. In contrast, the B(max) (34 fmol/mg protein) was unaffected by temperature. In human cortex, [(3)H]A-585539 bound with a K(d) of 0.066 nM and a B(max) of 5.8 fmol/mg protein at 4 degrees C, whereas under similar conditions, specific [(3)H]methyllycaconitine ([(3)H]MLA) binding was not measurable. A number of agonist and antagonist nAChR ligands displaced binding to rat brain membranes with rank order of affinity similar to that for [(3)H]MLA, and in general, a 5 to 10-fold higher affinity was observed for [(3)H]A-585539 binding. There was also a good correlation of K(i) values between [(3)H]A-585539 binding to rat brain and human cortex. The use of a alpha7/5-hydroxytryptamine type-3 chimera revealed that the N-terminal domain of alpha7 nAChR was sufficient to faithfully reproduce the pharmacology of [(3)H]A-585539 binding. Autoradiographic studies comparing [(3)H]A-585539 and [(125)I]alpha-bungarotoxin revealed a similar pattern of labeling in the rat. In summary, [(3)H]A-585539 was shown to have excellent binding characteristics in rat and human brain and represents the first high-affinity alpha7 agonist radioligand with utility in the characterization of this important nAChR subtype that is targeted toward ameliorating cognitive deficits underlying neuropsychiatric and neurodegenerative disorders.
AuthorsDavid J Anderson, William Bunnelle, Bruce Surber, Jia Du, Carol Surowy, Eliane Tribollet, Anouk Marguerat, Daniel Bertrand, Murali Gopalakrishnan
JournalThe Journal of pharmacology and experimental therapeutics (J Pharmacol Exp Ther) Vol. 324 Issue 1 Pg. 179-87 (Jan 2008) ISSN: 1521-0103 [Electronic] United States
PMID17959745 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • 2,2-dimethyl-5-(6-phenylpyridazin-3-yl)-5-aza-2-azoniabicyclo(2.2.1)heptane
  • AR-R 17779
  • Benzamides
  • Bridged Bicyclo Compounds
  • Bridged Bicyclo Compounds, Heterocyclic
  • Bridged-Ring Compounds
  • Bungarotoxins
  • Chrna7 protein, human
  • Chrna7 protein, rat
  • Nicotinic Agonists
  • Nicotinic Antagonists
  • PNU-282987
  • Pyridazines
  • Receptors, Nicotinic
  • Spiro Compounds
  • alpha7 Nicotinic Acetylcholine Receptor
  • methyllycaconitine
  • Nicotine
  • Aconitine
Topics
  • Aconitine (analogs & derivatives, metabolism)
  • Animals
  • Benzamides (metabolism)
  • Brain (metabolism)
  • Bridged Bicyclo Compounds (metabolism)
  • Bridged Bicyclo Compounds, Heterocyclic (metabolism)
  • Bridged-Ring Compounds (metabolism)
  • Bungarotoxins (metabolism)
  • Cell Line
  • Humans
  • Nicotine (metabolism)
  • Nicotinic Agonists (metabolism)
  • Nicotinic Antagonists (metabolism)
  • Pyridazines (metabolism)
  • Radioligand Assay
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Nicotinic (metabolism)
  • Spiro Compounds (metabolism)
  • alpha7 Nicotinic Acetylcholine Receptor

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: